Abilify (Aripiprazole): Indications, Dosing, and Monitoring
FDA-Approved Indications
Abilify is FDA-approved for five primary indications: schizophrenia, acute treatment of manic and mixed episodes in bipolar I disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and Tourette's disorder 1.
Critical Black Box Warnings
- Elderly patients with dementia-related psychosis have increased mortality risk and Abilify is not approved for this population 1.
- Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults when used as adjunctive antidepressant therapy; close monitoring is mandatory 1.
Dosing Recommendations by Indication
Schizophrenia
Adults:
- Starting and target dose: 10-15 mg once daily without regard to meals 1.
- Effective dose range is 10-30 mg/day, though doses above 10-15 mg/day show no additional efficacy 1.
- Wait minimum 2 weeks before dose increases to allow steady-state achievement 1.
- A starting dose of 10 mg achieves effective concentrations in most patients; 5 mg is sufficient for known CYP2D6 poor metabolizers 2.
Adolescents (13-17 years):
- Target dose: 10 mg/day 1.
- Start at 2 mg/day, titrate to 5 mg after 2 days, then to 10 mg after 2 additional days 1.
- Subsequent increases in 5 mg increments; 30 mg/day shows no superiority over 10 mg/day 1.
Bipolar I Disorder (Manic/Mixed Episodes)
Adults:
- Monotherapy: 15 mg once daily 1.
- Adjunctive therapy with lithium/valproate: 10-15 mg once daily 1.
- May increase to 30 mg/day based on clinical response; safety above 30 mg/day not established 1.
Pediatrics (10-17 years):
- Start at 2 mg/day, titrate to 5 mg after 2 days, target 10 mg/day after 2 additional days 1.
- Subsequent increases in 5 mg increments as needed 1.
Major Depressive Disorder (Adjunctive)
Adults:
- Starting dose: 2-5 mg/day added to existing antidepressant 1.
- Therapeutic range: 2-15 mg/day 1.
- Increase gradually in 5 mg increments at intervals of at least one week 1.
Irritability Associated with Autistic Disorder
Pediatrics (6-17 years):
- Therapeutic range: 5-15 mg/day 1.
- Start at 2 mg/day, increase to 5 mg/day, then to 10 or 15 mg/day if needed 1.
- Dose adjustments in 5 mg increments at minimum one-week intervals 1.
Dose Adjustments for Drug Interactions
The following adjustments are mandatory based on metabolic interactions 1:
| Clinical Factor | Dose Adjustment |
|---|---|
| Known CYP2D6 poor metabolizers | Administer half of usual dose |
| CYP2D6 poor metabolizers + strong CYP3A4 inhibitors | Administer quarter of usual dose |
| Strong CYP2D6 or CYP3A4 inhibitors | Administer half of usual dose |
| Strong CYP2D6 and CYP3A4 inhibitors | Administer quarter of usual dose |
| Strong CYP3A4 inducers | Double usual dose over 1-2 weeks |
Therapeutic Drug Monitoring
Therapeutic reference range for aripiprazole: 120-270 ng/mL (or 180-380 ng/mL for active moiety including dehydro-aripiprazole) 2. High interindividual variability and CYP2D6 genotype influence provide strong indication for therapeutic drug monitoring, particularly with oral and long-acting formulations 2.
Baseline and Ongoing Monitoring Requirements
Before Initiating Treatment
Obtain the following baseline measures 3:
- BMI and waist circumference
- Blood pressure
- HbA1c and fasting glucose
- Lipid panel
- Prolactin level
- Liver function tests
- Urea and electrolytes
- Complete blood count
- Electrocardiogram
Early Treatment Phase
- Recheck fasting glucose at 4 weeks (random glucose acceptable if fasting unavailable, then obtain fasting if abnormal) 3.
- Monitor BMI, waist circumference, and blood pressure weekly for 6 weeks 3.
Maintenance Monitoring
- Repeat all baseline measures at 3 months, then annually 3.
- Annual monitoring should include: liver function, HbA1c, renal function, and vitamin B12 if on metformin 3.
Hematologic Monitoring
- Patients with history of clinically significant low WBC or drug-induced leukopenia/neutropenia require frequent CBC monitoring during first months of therapy 1.
- Consider discontinuation at first sign of clinically significant WBC decline without other causative factors 1.
Special Clinical Considerations
Switching from Other Antipsychotics
Gradual cross-titration is preferred over abrupt switching 1. Maintain stable dose of prior antipsychotic until aripiprazole response is satisfactory, then taper previous agent slowly over several weeks 4. Minimize period of overlapping antipsychotic administration 1.
Managing Early Adverse Effects
Nausea, insomnia, and agitation occur in 10-20% of patients but typically resolve within 3-7 days 4. The primary goal is ensuring treatment completion through the first week with supportive concomitant medications if needed 4. These transient effects should not prompt premature discontinuation 4.
Use in Negative Symptoms
For predominant negative symptoms with well-controlled positive symptoms, aripiprazole or cariprazine are suitable options 3. Consider gradual antipsychotic dose reduction while remaining within therapeutic range if positive symptoms are stable 3.
Polypharmacy Context
Combining aripiprazole with another antipsychotic may reduce negative symptoms according to Finnish guidelines 3. Aripiprazole augmentation showed benefit for negative symptoms in meta-analysis (8 studies, N=532), though this was primarily in open-label trials 3. Aripiprazole augmentation may also reduce prolactin levels and body weight when added to other antipsychotics 3.
Key Safety Warnings
Pathological Gambling and Compulsive Behaviors
Consider dose reduction or discontinuation if pathological gambling or other compulsive behaviors emerge 1.
Orthostatic Hypotension
Monitor heart rate and blood pressure closely in patients with cardiovascular/cerebrovascular disease or risk of dehydration 1.
Seizure Risk
Use cautiously in patients with seizure history or conditions lowering seizure threshold 1.
Cognitive and Motor Impairment
Caution patients about operating machinery until effects are known 1.
Pediatric Considerations
Adverse effects are more significant in children and adolescents than adults, particularly weight gain, drowsiness, extrapyramidal effects, and metabolic effects 5. Severe adverse effects often occur with multiple-prescription settings 5. Off-label prescriptions should be limited as they account for significant aripiprazole use worldwide 5.
Practical Prescribing Pearls
- Aripiprazole demonstrates low potential for weight gain, sedation, sexual dysfunction, and adverse metabolic effects compared to other antipsychotics 4, 6.
- No dosage titration is necessary and the drug is effective within the first 1-2 weeks of treatment 6.
- Can be administered without regard to meals 1.
- Mean elimination half-life is approximately 75 hours for aripiprazole and 94 hours for active metabolite, with steady-state achieved by day 14 6, 7.
- Absolute oral bioavailability is 87% with peak plasma concentrations at 3 hours after multiple dosing 6.